Optimizing Homologous Recombination Deficiency (HRD) Testing Paradigms in Ovarian Cancer

Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD discuss the biological mechanisms behind homologous recombination deficiency (HRD) in ovarian cancer and expand on best practices for somatic and germline HRD testing and results-based patient management in the clinic.

EP. 1: Opening Remarks from Dr. Herzog, Dr. Krivak, and Dr. Hagemann

July 20th 2023

Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD open their discussion by introducing themselves and the objectives of the program.

EP. 2: Defining HRD and its Role in Ovarian Cancer

July 20th 2023

Experienced clinicians explain the role of the homologous recombination repair (HRR) pathway in DNA repair and how mutations in HRR-related genes, including BRCA1 and BRCA2, can cause homologous recombination deficiency (HRD) and contribute to the development and progression of ovarian cancer (OC).

EP. 3: Other Causes of HRD: Chromosomal LOH, LST, and TAI

July 27th 2023

Dr Hagemann explains how loss of heterozygosity (LOH), large-scale state transitions (LSTs), and telomeric allelic imbalance (TAI) can also contribute to HRD.

EP. 4: Commercially Available 
HRD Tests for Ovarian Cancer

July 27th 2023

The panel reviews commercially available HRD tests and expand upon factors that may influence test choice, such as clinical performance, institutional availability, turnaround time, and cost.

EP. 5: Leveraging HRD Testing Results in Ovarian Cancer: Clinical Data

August 2nd 2023

Discussion centered around data from the PAOLA-1 trial, highlighting the prevalence of BRCA1/2 mutations and HRD status in ovarian cancer, and how patients with these alterations may benefit from PARP inhibitor treatment.

EP. 6: HRD Testing in Ovarian Cancer: Clinical Guidelines Recommendations

August 2nd 2023

Panelists discuss clinical guidelines recommendations for HRD testing in ovarian cancer and how they inform their practice.